聚乙二醇化多西他赛白蛋白纳米粒用于非小细胞肺癌模型的实验研究

发布时间：2018-09-17 08:17

【摘要】：目的:制备聚乙二醇化多西他赛白蛋白纳米粒(PEG-albumin nanoparticles,PEG-DANPs),比较市售多西他赛(艾素~?,Aisu~?)、多西他赛白蛋白纳米粒(DANPs)和PEG-DANPs三者对裸鼠非小细胞肺癌模型的作用。方法:分别建立BALB/c裸鼠皮下移植瘤及原位癌模型,待皮下组肿瘤体积到达120 mm3时,两组模型分别通过尾静脉注射葡萄糖注射液,Aisu~?,DANPs和PEG-DANPs进行治疗,每7 d给药1次,共给药4次。在最后1次给药2 d后,将皮下移植瘤组和原位癌组所有裸鼠全部处死,取瘤块、肺脏、心脏、肝脏、脾送检HE(hematoxylin-eosin staining)染色切片。另选取裸鼠32只,建立皮下移植瘤模型,分别注射上述相同药物,持续治疗直至裸鼠自然死亡,最终统计并绘制裸鼠生存曲线。结果:PEG-DANPs能够有效地抑制裸鼠皮下移植瘤及原位癌的增殖,它能够有效地控制原位癌的转移并且延长裸鼠的生存时间。结论:PEGDANPs是一种抗肿瘤细胞效果明显、不良反应小的药物,具有广阔的应用前景。
[Abstract]:Aim: to prepare pegylated docetaxel albumin nanoparticles (PEG-albumin nanoparticles,PEG-DANPs) and compare their effects on nude mice non-small cell lung cancer (NSCLC) models with marketable docetaxel (DANPs), docetaxel albumin nanoparticles (DANPs) and PEG-DANPs. Methods: the models of subcutaneous transplanted tumor and carcinoma in situ were established in nude mice with BALB/c. When the tumor volume of subcutaneous group reached 120 mm3, the two groups were treated by injection of glucose injection (Aisutropium) DANPs and PEG-DANPs respectively every 7 days, for a total of 4 times. After the last administration for 2 days, all the nude mice in the subcutaneous transplanted tumor group and the carcinoma in situ group were killed and HE (hematoxylin-eosin staining) staining sections were taken from the tumor mass, lung, heart, liver and spleen. Another 32 nude mice were selected to establish the tumor model of subcutaneous transplantation. The same drug was injected into the nude mice. The treatment lasted until the nude mice died naturally. Finally, the survival curve of the nude mice was calculated and drawn. Results the cell proliferation of xenografted tumor and carcinoma in situ was inhibited effectively by 1% PEG-DANPs. It could effectively control the metastasis of carcinoma in situ and prolong the survival time of nude mice. ConclusionWith PEGDANPs is an effective antitumor drug with little adverse reaction, and has a broad application prospect.
【作者单位】：延边大学附属医院;中国医学科学院药物研究所天然药物活性物质与功能国家重点实验室药物传输技术及新型制剂北京市重点实验室;
【分类号】：R-332;R965

【相似文献】